TXNRD1 and non-small cell lung carcinoma: They found that of the series of prodrugs studied, one of the prodrugs (125) containing an alkyl amide group showed the most potent anti-NSCLC activity and efficiently released the active compound from the prodrug, which then formed a covalent bond with a novel Cys475 site and a known Sec498 site of TrxR1.